Close

Jump to:

  • Navigation
  • Content
  • Footer
Quin hero image

Quin

Follow

A mobile medical app that helps people decide how much insulin to take. Humanising diabetes technology.

115%
 - 
Funded 5 Mar 2020
£600,003 target
£691,497 from 260 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website quintech.io/
Sectors Healthcare Digital B2C
Company number 09206022
Incorporation date 5 Sep 2014
More
Less

Investment summary

Type Equity
Valuation (pre-money) £6.8M
Equity offered 9.28%
Tax relief

EIS

More
Less

Business highlights

  • £1.94M raised so far in grants and angel funding
  • 76% of Quin users feel better about living with diabetes
  • Selected by Apple for insider access to engineers and execs
  • Founder is a robotics engineer living with diabetes for 26 years
More
Less

Key features

  • Secondary Market
  • Seedrs nominee min. £13.14 +
  • Pay by Bank payments not accepted
  • Idea
  • Key Information
  • Team
  • Updates
  • Investors 260
  • Discussion
  • Documents

Idea

Introduction

We are humanising diabetes technology for better health outcomes and quality of life.

PROBLEM
An estimated 92% of nearly 40 million people with insulin-treated diabetes do not achieve recommended medical targets. They’re 2-3 times more likely to have anxiety and depression. Why? The science of diabetes is incomplete, so people fill the gaps with their own trial and error and diabetes technology.

SOLUTION
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones to help people decide how much insulin to take and when. We are structuring this data to reveal insights into the causes behind fluctuations in blood glucose and expand diabetes science.

In the past 2 years, 100+ people who take insulin have been guiding our R&D. 76% of Quin users feel better about living with diabetes and 35% have improved their HbA1c – healthcare’s target measure. We now want to launch Quin and help more people achieve the target with a better quality of life.

Intended impact

Our founder, Isabella, has been living with type 1 diabetes for 26 years. Quin’s vision was born from her love for making machines do things people don’t want to do while making hundreds of diabetes decisions a day.

At diagnosis, people are given general medical formulas to calculate how much insulin to take for what they eat. Those formulas don’t accurately reflect what goes on in their body. So, people use trial and error to personalise them for everything they do: eating, moving, working, sleeping – all aspects of their daily life.

The latest diabetes technology seeks to refine the general medical formulas to personalise insulin dosing. But if they don’t work for people, they won’t work for technology either.

Quin takes a different approach. It’s based on the principle that your past insulin-dosing decisions – not medical formulas – are the most reliable basis for your future insulin-dosing decisions. It’s human-first, and our early data shows it works.

Substantial accomplishments to date

76% of Quin users feel better about living with diabetes, and 35% have improved their HbA1c – healthcare’s target measure.

Apple has granted us insider access to their engineers and executives who are helping us get Quin to market.

Our proven multi-disciplinary team of 12 is highly skilled in engineering, design, product, and marketing, and we have an extensive network of committed professional advisors. Our app has a class I CE Mark, and we have 2 patents pending. We have raised £1.94M in grants and angel funding.

Forbes recently featured Quin: How This App Could Transform Diabetes Management For Millions Across The World https://www.forbes.com/sites/nicholasfearn/2020...

Innovate UK and UK Research and Innovation have showcased Quin as a leading-edge healthcare innovation: https://www.gov.uk/government/case-studies/diab...

Monetisation strategy

Our business model will generate revenue from both business-to-consumer (B2C) and business-to-business (B2B) opportunities.

The Quin app will be made available to consumers via the Apple app store on a monthly subscription fee basis. Payment will be made either by reimbursement from the healthcare payer/provider or directly out of pocket. Customers will be acquired through inbound digital marketing, distribution partnerships, and healthcare payer/providers.

The global market for diabetes devices, covering glucose monitoring and insulin delivery, was valued at $21.7B in 2017, and is expected to expand to $32.9B in 2025. The global insulin market is predicted to reach $70.6 billion by 2023.

Quin’s data and algorithms will make these drugs and devices much more personalised and effective, and B2B revenue streams will flow from these opportunities in the future.

Use of proceeds

We have a proven team and processes in place to support our research and development, user safety and regulatory compliance needs. We are raising Seedrs funds alongside funds from angel investors to support the launch of the Quin app. Our Seedrs proceeds will go almost exclusively towards:

- Hiring a product designer to enhance the user experience

- Achieving ISO 13485 certification and compliance with new European Medical Device Regulations

- Hiring a marketer and building out our infrastructure and capabilities to acquire and manage thousands of customers after launch

- Developing B2B2C distribution partnerships

- Launching the Quin app in the UK and Europe in late 2020

Key Information

The Company has one outstanding loan of £100k from ThoughtWorks for software development services. The repayment date for this loan is subject to negotiation but is due to be repaid during the course of the raise. The proceeds of the raise will not be used to repay this loan.

Open an account to get access to the team members of Quin

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This webpage has been approved as a financial promotion by Seedrs Limited ("Seedrs"), which is authorised and regulated by the Financial Conduct Authority. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. The summary information provided about investment opportunities on this webpage is intended solely to demonstrate the types of investments available on the Seedrs platform, and any investment decision should be made on the basis of the full campaign. Full campaigns are available to investors who have become authorised to invest on the Seedrs platform. All investment activities take place within the United Kingdom, and any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing.

Seedrs does not make investment recommendations to you. No communications from Seedrs, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Seedrs does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Seedrs, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £6,753,763

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

Pitch type

There are 5 types of investment pitch available on Seedrs.

  • Equity
  • Convertible
  • Fund
  • Cohort
  • Secondary

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Seedrs nominee

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Seedrs nominee.

Find out more

Custodian

If you invest in this Campaign, Seedrs will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Seedrs will not benefit from any rights under a shareholder agreement. As a result, Seedrs will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

This is an option to invest and hold shares 'directly' in the company (rather than via the Seedrs Nominee). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Seedrs. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Warning

You are following a link outside of www.seedrs.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel